Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.39 |
| ▸ | AHR | P35869 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | FABP6 | P51161 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30023822 | 1.00 | MAPT (0.49) | MAPTALDH1A1GAAHSD17B10LMNA | |
| SCHEMBL15479695 | 0.90 | LMNA (0.61) | MAPTALDH1A1GAAHSD17B10LMNA | |
| SCHEMBL31133734 | 0.87 | MAPT (0.44) | MAPTALDH1A1GAAHSD17B10LMNA | |
| SCHEMBL304283 | 0.85 | MAPT (0.62) | MAPTALDH1A1GAAHSD17B10LMNA | |
| SCHEMBL30895878 | 0.85 | MAPT (0.62) | MAPTALDH1A1GAAHSD17B10LMNA | |
| Hydrochloric Acid SCHEMBL1820257 | 0.83 | MAPT (0.61) | MAPTALDH1A1GAAHSD17B10LMNA | |
| SCHEMBL15479709 | 0.83 | LMNA (0.53) | MAPTALDH1A1GAAHSD17B10LMNA | |
| SCHEMBL17423918 | 0.80 | BLM (0.42) | MAPTLMNAHTTBLMAHR | |
| SCHEMBL24820913 | 0.77 | ALDH1A1 (0.49) | MAPTALDH1A1GAAHSD17B10HDAC11 | |
| SCHEMBL2746377 | 0.77 | ALDH1A1 (0.49) | MAPTALDH1A1GAAHSD17B10HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720057-A2 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260078134-A1 | Macrocyclic Compounds as RAS Inhibitors | BEONE MEDICINES I GMBH (CH) | 2026-03-19 | — | — | US | disclosed |
| US-12570648-B2 | 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer | LES LABORATOIRES SERVIER (FR) | 2026-03-10 | — | — | US | disclosed |
| US-20260015321-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED (GB) | 2026-01-15 | — | — | US | disclosed |
| US-20250382285-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-12486251-B2 | CBP/EP300 inhibitor and use thereof | PHARMABLOCK SCIENCES (NANJING) , INC. (CN) | 2025-12-02 | — | — | US | disclosed |
| US-20250333407-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-10-30 | — | — | US | disclosed |
| WO-2025201477-A1 | SPIROCYCLIC GSDME INHIBITORS | PYROTECH (BEIJING) BIOTECHNOLOGY CO.,LTD. (CN) | 2025-10-02 | — | — | WO | disclosed |
| EP-2084155-A1 | THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-08-05 | — | — | EP | disclosed |
| EP-2035436-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008047109-A1 | THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008001076-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-01-03 | — | — | WO | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1056728-B1 | DIHYDRO-BENZO(1,4)OXAZINES AND TETRAHYDROQUINOXALINES | AVENTIS PHARMA LTD (GB) | 2007-11-21 | — | — | EP | disclosed |
| US-6632814-B1 | Dihydro-benzo(1,4)oxazines | AVENTIS PHARMA LTD. (GB) | 2003-10-14 | — | — | US | disclosed |
| EP-1056728-A1 | DIHYDRO-BENZO(1,4)OXAZINES AND TETRAHYDROQUINOXALINES | Aventis Pharma Limited (GB) | 2000-12-06 | — | — | EP | disclosed |
| WO-2000039103-A1 | DIHYDRO-BENZO(1,4)OXAZINES AND TETRAHYDROQUINOXALINES | AVENTIS PHARMA LIMITED (GB) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | MAPT 1299/4885ALDH1A1 2876/4885GAA 986/4885 |
| US-20260078134-A1 | Macrocyclic Compounds as RAS Inhibitors | NRAS, KRAS, HRAS | MAPT 4125/4885ALDH1A1 2557/4885GAA 3111/4885 |
| US-20260015321-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | WRN, MSH2, MSH6 | MAPT 4063/4885ALDH1A1 1151/4885GAA 1967/4885 |
| US-12570648-B2 | 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer | BCOR, BCL2A1, BAK1 | MAPT 4819/4885ALDH1A1 2522/4885GAA 4749/4885 |
| US-20250382285-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | MAPT 1299/4885ALDH1A1 2876/4885GAA 986/4885 |
| US-12486251-B2 | CBP/EP300 inhibitor and use thereof | EP300, CREBBP, BPTF | MAPT 2797/4885ALDH1A1 2314/4885GAA 4668/4885 |
| US-20250333407-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | HBG1, HBG2, HBB | MAPT 4543/4885ALDH1A1 424/4885GAA 107/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | MAPT 4259/4885ALDH1A1 100/4885GAA 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.